Download Sample Brochure @ http://tinyurl.com/hsennl5 Marketintelreports, ‘Multiple Myeloma (Kahler Disease) - Pipeline Review, H2 2015’, provides an overview of the Multiple Myeloma (Kahler Disease)’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Multiple Myeloma (Kahler Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Multiple Myeloma (Kahler Disease) and special features on late-stage and discontinued projects.
Big Market Research : Juvenile Macular Degeneration (Stargardt Disease) - Pipeline Review, H2 2014 To Get More Details @ http://www.bigmarketresearch.com/juvenile-macular-degeneration-stargardt-disease-pipeline-review-h2-2014-market This report provides comprehensive information on the therapeutic development for Juvenile Macular Degeneration (Stargardt Disease), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Juvenile Macular Degeneration (Stargardt Disease) and special features on late-stage and discontinued projects.
Gene Therapy Infectious Disease Insight: Pipeline Assessment, Technology Trend, and Competitive Landscape provides the information across the gene therapy value chain covering gene therapy profiles core insights, pre-clinical data, clinical data, technology details, funding and licensing opportunities. See Full Report @ http://bit.ly/1z9iGja
Chronic Kidney Disease (Chronic Renal Failure)-Pipeline Insights, 2015, report provides comprehensive insights about pipeline drugs across this Chronic Kidney Disease (Chronic Renal Failure). A key objective of report is to establish the understanding for all the pipeline drugs that fall under Chronic Kidney Disease (Chronic Renal Failure). See Full Report: http://bit.ly/1GfBq3w
The Cardiovascular Disease (CVD) therapy area encompasses a range of different diseases and conditions affecting the heart and/or blood vessels. The most crucial risk factors for CVD are hypertension and dyslipidemia, which accelerate the development of atherosclerotic plaque build up within blood vessels. For more information on the research report, refer to below link:- https://www.kenresearch.com/healthcare/pharmaceuticals/global-cardiovascular-disease-drugs-market-to-2023/142623-91.html
This report provides comprehensive information on the therapeutic development for Fatty Liver Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Fatty Liver Disease and special features on late-stage and discontinued projects. See Full Report @ bit.ly/1Bv2LJA
Download Sample Brochure@ http://tinyurl.com/hc8c6pj Markeintelreports, ‘Alzheimer's Disease - Pipeline Review, H2 2015’, provides an overview of the Alzheimer's disease’s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Alzheimer's disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Alzheimer's disease and special features on late-stage and discontinued projects.
Due to loss of patent for major brands in the late-stage chronic kidney disease (CKD) market, and the changing reimbursement environment across the six major markets (6MM), the CKD sales revenue is forecasted to decrease at a negative CAGR of 2.5% between 2012 and 2017. The late-stage CKD therapeutics market in the 6MM (US, France, Germany, Italy, Spain, and UK) will decline from USD 1.88 billion in 2012 to USD 1.66 billion by 2017. It is expected that the majority of sales in the will still come from the US (76%), with marginal increase in the 5EU’s share (24%) during 2012 to 2017. Visit : http://www.researchonglobalmarkets.com/opportunityanalyzer-late-stage-chronic-kidney-disease-ckd-opportunity-analysis-and-forecasts-to-2017.html
Download Sample Brochure of Report @ http://tinyurl.com/ja94rae A detailed qualitative analysis of the factors responsible for driving and restraining growth of the MRI Systems Market and future opportunities are provided in the report.
Download Sample Brochure @ http://tinyurl.com/zoxut3l A detailed qualitative analysis of the factors responsible for driving and restraining growth of the Batten Disease – Pipeline Review and future opportunities are provided in the report.
Big Market Research adds a report “Pancreatic Cancer Therapeutics in Major Developed Markets- Size, Share, Trends, Forecast, Growth, Opportunities, Outlook " Get Complete Report @ http://www.bigmarketresearch.com/pancreatic-cancer-therapeutics-in-major-developed-to-2021-strong-late-stage-pipeline-holds-promise-for-increasingly-diverse-landscape-market The current late-stage drugs in development for PC address this clinical need; however, results so far have been limited in their efficacy, with none demonstrating clinically transformative efficacy or safety. As a result, the growth in PC prevalence as a result of a global aging population, increasing diabetes and obesity prevalence is expected to be the key driver of this market throughout the forecast period. Enquire about this report @ http://www.bigmarketresearch.com/report-enquiry/373733
The Parkinsons disease (PD) pipeline currently has 302 products in active development across all stages, but a stark contrast between the mechanisms of action employed in the current market and the pipeline is evident. Where the market relies on symptomatic treatments that target neuromodulatory receptors, the pipeline shows a diverse range of neuroprotective therapies targeting dysfunctional disease processes. See Full Report : http://bit.ly/14ZURze
Download Sample Brochure @ http://tinyurl.com/ja94rae A detailed qualitative analysis of the factors responsible for driving and restraining growth of the Alzheimer’s Disease Therapeutics and future opportunities are provided in the report.
The report provides an estimation of the market size for 2012, along with market forecasts to 2019. It also covers disease epidemiology, treatment algorithms, treatment patterns, in-depth analysis of the pipeline, and deal analysis.The global pancreatic adenocarcinoma therapeutics market is expected to grow from approximately $856m in 2012 to $1.2 billion in 2019, with growth driven by small changes in multiple factors. Detailed report at: http://www.reportsandintelligence.com/pancreatic-adenocarcinoma-therapeutics-in-major-developed-to-2019-early-stage-pipeline-shows-diversity-of-novel-targets-though-commercial-impact-remains-distant-market
Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The disease is often asymptomatic, but infected patients may experience fatigue, joint pain, itchy skin or jaundice. There is no effective vaccine against HCV, so the market is driven by therapeutics. See Full Report @ bit.ly/ZrFfRz
Big Market Research has announced a new report “COPD Therapeutics in Major Developed Markets - Size, Share, Trends, Forecast, Growth, Opportunities 2021” Get Complete Report @ http://www.bigmarketresearch.com/copd-therapeutics-in-major-developed-to-2021-emergence-of-addition-in-class-and-first-in-class-products-offsets-sales-erosion-of-leading-brands-market There are currently 203 products in active development, excluding four with an unknown stage of development. Although many of the targets identified in the pipeline are well established in the management of COPD, there are some novel, first-in-class targets. This reflects the growing understanding of the underlying mechanisms that characterize the disease. Enquire about this report @ http://www.bigmarketresearch.com/report-enquiry/373731
RnRMarketResearch.com adds “Juvenile Macular Degeneration (Stargardt Disease) – Pipeline Review, H1 2015” to its store. This report provides comprehensive information on the therapeutic development for Juvenile Macular Degeneration (Stargardt Disease), complete with comparative analysis at various stages.
Type 2 Diabetes Mellitus (T2DM) is a metabolic disease characterized by chronic hyperglycemia (high blood glucose levels). Global prevalence has risen rapidly in the past several decades, particularly in line with obesity. This has been attributed to a range of factors, including economic development, increasing urbanization, aging populations, and changes in lifestyle patterns such as reduced levels of physical activity and consumption of higher-calorie diets. Enquiry @ http://www.researchbeam.com/type-2-diabetes-mellitus-therapeutics-in-major-developed-to-2021-strong-pipeline-and-expanding-treatment-population-to-encourage-robust-growth-market/enquire-about-report
Immunetics Inc. (Immunetics) offers assay technology for blood screening and infectious disease diagnosis. It is one of the leading innovator of tests for bacterial, viral, and parasitic diseases. It produces and markets a wide range of infectious disease assay kits and instruments. Immunetics has issued patents on its BacTx test for bacterial contamination of platelets.
Lab21 Limited (Lab21) is a personalized healthcare company. The company offers diagnostic products and services and supports medical diagnostics, blood bank screening and drug discovery. Lab21serves pharmaceutical and diagnostic firms and international healthcare providers. Lab21s diagnostic product division manufactures immuno-diagnostic kits and reagents which is focused on infectious diseases for the blood banking and clinical markets.
IV Diagnostics, Inc. (IV Diagnostics) is a biomedical diagnostic company that concentrates on molecular diagnostic tests for circulating tumor cells and other blood borne diseases. The company develops, tests and markets diagnostic tools that monitor and measure cancer tumor cells. Its IVDxTx platform technology, allows physicians to perform real-time diagnosis of the patient’s circulating tumor cells (CTCs) without collecting blood.
Multiple Myeloma (MM) is a hematological malignancy characterized by the proliferation of plasma cells in the bone marrow. It is the second-most frequently diagnosed hematological malignancy, with an annual prevalence in the US of about 45,000. The disease is considered incurable, although the past decade has seen significant improvements in therapy, driven by a greater understanding of pathophysiology. Many of the leading drugs in the market were approved over the past 10–15 years, and have improved median survival rates by about 50%. Enquiry @ http://www.researchbeam.com/multiple-myeloma-therapeutics-in-major-developed-to-2021-growth-driven-by-rising-prevalence-continued-success-of-revlimid-and-emerging-supplementary-treatments-market/enquire-about-report
The liver cancer pipeline contains 238 products in active development, approximately 47% of which are first-in-class. The percentage of the pipeline devoted to innovative products is considerably larger than both the industry and oncology average, which is a promising sign for novel therapeutics reaching the liver cancer market. Enquiry @ http://www.researchbeam.com/frontier-pharma-liver-cancer-identifying-and-commercializing-first-in-class-innovation-market/enquire-about-report
Hepatitis B is an infectious liver disease caused by the Hepatitis B Virus (HBV) and characterized by acute or chronic inflammation of the liver. Despite its status as a vaccine-preventable disease, it remains a serious global health concern. Incidence tends to be higher in countries with a significant number of migrants from medium and high-prevalence countries. Enquiry @ http://www.researchbeam.com/hepatitis-b-therapeutics-in-major-developed-to-2021-increasing-number-of-migrants-from-high-prevalence-regions-to-drive-growth-market/enquire-about-report
Big Market Research present “PharmaPoint: Prostate Cancer - Global Drug Forecast and Market” Size, Share, Industry Trends, Demand, Analysis, Research, Report, Company Profiles, Forecast to 2023. Visit for more info @ http://www.bigmarketresearch.com/pharmapoint-prostate-cancer-global-drug-forecast-and-analysis-to-2023-market Prostate cancer is the second most common cancer in men worldwide, after skin cancer. It accounts for 15% of all the cancers diagnosed in men, and thus represents a huge burden on healthcare systems. While patients diagnosed with early-stage, localized prostate cancer can be cured, patients who are diagnosed with or progress to castration-resistant prostate cancer (CRPC) have no curative options.
Large and Diverse Pipeline The liver cancer pipeline contains 238 products in active development, approximately 47% of which are first-in-class. The percentage of the pipeline devoted to innovative products is considerably larger than both the industry and oncology average, which is a promising sign for novel therapeutics reaching the liver cancer market. Get more about this report at: http://www.bigmarketresearch.com/frontier-pharma-liver-cancer-identifying-and-commercializing-first-in-class-innovation-market
Download Sample Brochure @ http://tinyurl.com/h36neux A detailed qualitative analysis of the factors responsible for driving and restraining growth of the Parkinson’s Disease Therapeutics and future opportunities are provided in the report.
GBI Research, has released its latest pharma report, "Acute Myeloid Leukemia Therapeutics Market to 2020 - Novel Therapies to Offer Clinical Benefit in Small Patient Cohorts" Treatment and prognosis in AML is strongly influenced by a patient’s age, and their cytogenetic profile. In the majority of cases these two prognostic influences are linked, with a higher frequency of unfavorable cytogenetic abnormalities observed in the elderly. Enquiry @ http://www.researchbeam.com/acute-myeloid-leukemia-therapeutics-to-2020-novel-therapies-to-offer-clinical-benefit-in-small-patient-cohorts-market/enquire-about-report
Big Market Research presents this report which features an analysis of granted patent applications in the liver cancer market, which was used as an indication of innovation at the earliest stage of product development. Read The Complete Report On : http://www.bigmarketresearch.com/frontier-pharma-liver-cancer-identifying-and-commercializing-first-in-class-innovation-market
Alfa Wassermann Diagnostic Technologies, LLC (AWDT) is the provider of medical diagnostic instrumentation and reagents to the medical community. It offers diagnostics equipment to the physician office and veterinary lab markets. The product portfolio of the company comprises ACE Axcel Clinical Chemistry System, ACE Alera Chemistry System, Alfa Laboratory Information System (LIS), Vet Alera Chemistry Analyzer and Vet LIS. It operates as the subsidiary of Alfa Wassermann, Inc. AWDT is headquartered in New Jersey, the US.
Only one older generation drug with modest efficacy had been available until the recent arrival of two new therapies that could potentially change the prescribing landscape. Will these drugs make a significant impact on the Obesity market? Which drugs are used off-label for the treatment of obesity?
‘Kidney Disease - Pipeline Review, H1 2014’, provides an overview of the Kidney Disease’s therapeutic pipeline.This report provides comprehensive information on the therapeutic development for Kidney Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. See Full Report : http://bit.ly/1DNJ99m
The “Parkinsons disease” (PD) pipeline currently has 302 products in active development across all stages, but a stark contrast between the mechanisms of action employed in the current market and the pipeline is evident. For More Details: http://goo.gl/a4BN91
Hepatitis C Therapeutics in Major Developed Markets to 2019 - Outstanding Recent Approvals and Late-Stage Pipeline to Transform Clinical and Commercial Landscape. The current Hepatitis C treatment landscape consists of a combination of pegylated interferon, ribavirin and, in patients infected with genotype 1 hepatitis C, one of two direct-acting antiviral agents (DAAs). Browse full report @ http://bit.ly/1zyVhVi
Big Market Research, Global PharmaPoint HER2-Positive Breast Cancer Drug Market Size, Share, Trends, Application, Forecast, Demand, Analysis, Research, Report, Opportunities, Segmentation, to 2023. HER2-positive breast cancer is the second most common cancer in the world and the most common cancer in women worldwide. This report focuses on the current treatment landscape, unmet needs, current pipeline, and commercial opportunities in the HER2-positive breast cancer market, with coverage of multiple settings of the disease including neoadjuvant, adjuvant, first-, second-, third-, and fourth-line metastatic. This report forecasts that the two monoclonal antibodies that also target the HER2 receptor will ensure Roche still occupies over 95% of the market in 2023. The challenge for new entrants into the HER2-positive market is to find patient populations that are currently underserved, and can work cooperatively with Roche’s targeted therapies.
Big Market Research, Global Pharma Point Colorectal Cancer Drug Market Size, Share, Trends, Application, Forecast, Demand, Analysis, Research, Report, Opportunities, Segmentation to 2023. Colorectal cancer (CRC) is the second leading cause of mortality among cancer patients in the world and is the third most diagnosed cancer globally, and thus represents a huge burden on healthcare systems. By 2023, the end of the forecast period, GlobalData projects CRC sales to rise to $8.11 billion in the 8MM, at a moderate Compound Annual Growth Rate (CAGR) of 4.9%. Major drivers of the growth of the CRC market over the forecast period include increasing CRC incident cases, the launch of premium-priced adjuvant and maintenance treatments for first-line metastatic disease, and the launch of pipeline agents for later-line CRC. Annualized Colorectal cancer therapeutics market revenue, annual cost of therapy, and treatment usage patterns in eight patient segments, forecast from 2013 to 2023.
Big Market Research, PharmaPoint: Global Asthma Drug Market Size, Share, Strategies, Trends, Application, Forecast, Demand, Analysis, Research, Report, Opportunities. Big Market Research added a new research report "PharmaPoint: Asthma - Global Drug Forecast and Market Analysis to 2023". Asthma accounts for approximately 250,000 deaths around the world annually, deaths that otherwise could be easily prevented through appropriate treatment The asthma market saw very slow growth over the past decade. The largest unmet needs mainly reflect the high level of heterogeneity of the disease, the lack of patient compliance with the standard therapies, and the high cost of medications for asthma treatment. In addition, there is a lack of diagnostic tools to provide a reliable diagnosis of asthma in young children. Annualized asthma therapeutics market revenue, annual cost of therapy and treatment usage pattern data from 2013 and forecast for ten years to 2023.
The industry analysis specialist, has released its new report, “Hepatitis A Preventive Vaccines - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Hepatitis A Preventive Vaccines market. See Full Report @ http://bit.ly/1B1b2b6
The industry analysis specialist, has released its new report, “Polycystic Kidney Disease (PKD) Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Polycystic kidney disease Therapeutics market. The report identifies the key trends shaping and driving the global Polycystic kidney disease Therapeutics market. See Full Report @ bit.ly/1CnYvQS
The industry analysis specialist, has released its new report, “Psychotic Depression Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Psychotic Depression Therapeutics market. See Full Report @ bit.ly/1y8uJOl
The industry analysis specialist, has released its new report, “Graves’ Disease Therapeutics - Pipeline Assessment and Market Forecast to 2019”. The report is an essential source of information and analysis on the global Graves Disease Therapeutics market. The report identifies the key trends shaping and driving the global Graves Disease Therapeutics market. See Full Report @ bit.ly/1HpdSto
The report is an essential source of information and analysis on the global Atherosclerosis or Coronary Artery Disease (CAD) Therapeutics market. The report identifies the key trends shaping and driving the global Atherosclerosis or Coronary Artery Disease (CAD) Therapeutics market. For more information : http://bit.ly/1Agi78w
The industry analysis specialist, has released its new report, “Ankylosing Spondylitis Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Ankylosing Spondylitis Therapeutics market. The report identifies the key trends shaping and driving the global Ankylosing Spondylitis Therapeutics market. See Full Report @ bit.ly/1HpdGtZ
The industry analysis specialist, has released its new report, “Leiomyosarcoma Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Leiomyosarcoma Therapeutics market. The report identifies the key trends shaping and driving the global Leiomyosarcoma Therapeutics market. See Full Report @ bit.ly/1uVOPo9
The industry analysis specialist, has released its new report, Interstitial Cystitis Therapeutics - Pipeline Assessment and Market Forecasts to 2019. The report is an essential source of information and analysis on the global Interstitial Cystitis Therapeutics market. The report identifies the key trends shaping and driving the global Interstitial Cystitis Therapeutics market. See Full Report @ bit.ly/1uxFK9v
The industry analysis specialist, has released its new report, “Hepatic Encephalopathy Therapeutics - Pipeline Assessment and Market Forecasts to 2019”. The report is an essential source of information and analysis on the global Hepatic Encephalopathy Therapeutics market. The report identifies the key trends shaping and driving the global Hepatic Encephalopathy Therapeutics market. For more information : http://bit.ly/1wqiSVp
The industry analysis specialist, has released its new report, Graves Disease Therapeutics - Pipeline Assessment and Market Forecast to 2019. The report is an essential source of information and analysis on the global Graves Disease Therapeutics market. The report identifies the key trends shaping and driving the global Graves Disease Therapeutics market. For more information : http://bit.ly/1xOeumU
Reports and Intelligence adds a report on “Non-Hodgkin Lymphoma Therapeutics in Major Developed Markets to 2020 - New Entrants and Promising Pipeline Widen Targeted and Immunotherapeutic Treatment Options”. The report is designed with an aim to provide the market investors with full-fledged knowledge of the market trends and factors influencing the growth of the market. Detailed report at: http://www.reportsandintelligence.com/non-hodgkin-lymphoma-therapeutics-in-major-developed-to-2020-new-entrants-and-promising-pipeline-widen-targeted-and-immunotherapeutic-treatment-options-market
Global & USA Cancer Biomarker Market to 2018 (Identification, Technologies, Market Analysis, Competitor Profiles, Companion Diagnostic Co-development, Business Strategies, Industry Trends, and Pipeline Analysis)” is a comprehensive report on the cancer biomarker industry and its impact on the health system. This report tackles the growing market interest in oncogenic biomarkers, personalized medicine, companion diagnostics and the associated market environment. Complete report available @ http://www.lifescienceindustryresearch.com/global-usa-cancer-biomarker-market-to-2018-identification-technologies-market-analysis-competitor-profiles-companion-diagnostic-co-development-business-strategies-industry-trends-and-pipelin.html.
The report is an essential source of information and analysis on the global Narcolepsy Therapeutics market. The report identifies the key trends shaping and driving the global Narcolepsy Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. For more information : http://bit.ly/1wDZ3NU
The industry analysis specialist, has released its new report, Paroxysmal Nocturnal Hemoglobinuria (PNH) Therapeutics - Pipeline Assessment and Market Forecasts to 2019. The report is an essential source of information and analysis on the global Paroxysmal Nocturnal Hemoglobinuria Therapeutics market. For more information : http://bit.ly/1zvbVqb
The report identifies the key trends shaping and driving the global Athletes Foot Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. For more information : http://bit.ly/1vV3RPK
The report identifies the key trends shaping and driving the global Polycystic kidney disease Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Polycystic kidney disease Therapeutics sector. For more information : http://bit.ly/1rM17Po
A leading business intelligence provider, has released its latest research report "Cystic Fibrosis Therapeutics in Major Developed Markets to 2019 CFTR Modulators Initiate Drive towards Personalized Treatment and Market Growth".
The report is an essential source of information and analysis on the global Pompe Disease (GAA Deficiency) Therapeutics market. The report identifies the key trends shaping and driving the global Pompe Disease (GAA Deficiency) Therapeutics market. For more information : http://bit.ly/1ArN07b